Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3281991 | Clinical Gastroenterology and Hepatology | 2014 | 28 Pages |
Abstract
Seven drugs have been approved for the treatment of chronic hepatitis B. Antiviral treatment has been shown to be effective in suppressing hepatitis B virus replication, decreasing inflammation and fibrosis in the liver, and preventing progression of liver disease. However, current medications do not eradicate hepatitis B virus; therefore, a key question is which patients need to start treatment and which patients can be monitored. Professional societies have developed guidelines to assist physicians in recognition, diagnosis, and optimal management of patients with chronic hepatitis B. These guidelines suggest preferred approaches, and physicians are expected to exercise clinical judgment to determine the most appropriate management based on the circumstances of the individual patient. This article reviews recommendations in hepatitis B guidelines and the basis for those recommendations, and we discuss what we do in our practice to illustrate factors that may influence decisions regarding hepatitis B management.
Keywords
APASLpegylated-interferonhepatitis B e antibodyEASLALTAASLDCHBULNPEG-IFNHBeAgHBsAgHCCα-fetoproteinAlanine aminotransferaseHepatitis B surface antigenAsian Pacific Association for the Study of the LiverAmerican Association for the Study of Liver DiseasesEuropean Association for the Study of the LiverinterferonIFNAFPUpper limit of normalAntiviral therapyanti-HBcAnti-HBeManagementnucleos(t)ide analogueHepatitis B e antigenchronic hepatitis Bhepatitis B core antibodyHBVhepatitis B virusHepatocellular carcinomanuc
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Suna Yapali, Nizar Talaat, Anna S. Lok,